Skip to main content

Physician Utilization Patterns for VEGF-Inhibitor Drugs in the 2012 United States Medicare Population: Bevacizumab, Ranibizumab, and Aflibercept.

Publication ,  Journal Article
Baisiwala, S; Bundorf, MK; Pershing, S
Published in: Ophthalmic surgery, lasers & imaging retina
June 2016

To evaluate variation in physician use of vascular endothelial growth factor (VEGF) inhibitors.Population-based analysis of comprehensive, publicly available 2012 Medicare claims, aggregated by physician specialty and service type - including intravitreal injections of bevacizumab (Avastin; Genentech, South San Francisco, CA), ranibizumab (Lucentis; Genetech, South San Francisco, CA), and aflibercept (Eylea; Regeneron, Tarrytown, NY). Physicians were characterized by total patients treated, proportion treated with each drug, total intravitreal injection payments, and proportion of total payments for each drug.The authors identified 2,869 ophthalmologists. On average, each treated 203 patients with VEGF-inhibitors, 75.9% of which were treated with bevacizumab. Using all three agents was the most common practice (1,121 physicians), closely followed by using bevacizumab only (1,061 physicians). Ranibizumab accounted for most payments, but bevacizumab was the largest payment source for a sizeable proportion of physicians who used only/mostly bevacizumab.Most ophthalmologists use multiple VEGF inhibitors, but vary in their relative use. A subset of ophthalmologists predominantly use ranibizumab, but ophthalmologists overall use more bevacizumab despite financial incentives favoring ranibizumab. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:555-562.].

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ophthalmic surgery, lasers & imaging retina

DOI

EISSN

2325-8179

ISSN

2325-8160

Publication Date

June 2016

Volume

47

Issue

6

Start / End Page

555 / 562

Related Subject Headings

  • Vascular Endothelial Growth Factor A
  • United States
  • Tomography, Optical Coherence
  • Retrospective Studies
  • Recombinant Fusion Proteins
  • Receptors, Vascular Endothelial Growth Factor
  • Ranibizumab
  • Population Surveillance
  • Ophthalmologists
  • Medicare
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Baisiwala, S., Bundorf, M. K., & Pershing, S. (2016). Physician Utilization Patterns for VEGF-Inhibitor Drugs in the 2012 United States Medicare Population: Bevacizumab, Ranibizumab, and Aflibercept. Ophthalmic Surgery, Lasers & Imaging Retina, 47(6), 555–562. https://doi.org/10.3928/23258160-20160601-07
Baisiwala, Shivani, M Kate Bundorf, and Suzann Pershing. “Physician Utilization Patterns for VEGF-Inhibitor Drugs in the 2012 United States Medicare Population: Bevacizumab, Ranibizumab, and Aflibercept.Ophthalmic Surgery, Lasers & Imaging Retina 47, no. 6 (June 2016): 555–62. https://doi.org/10.3928/23258160-20160601-07.
Baisiwala S, Bundorf MK, Pershing S. Physician Utilization Patterns for VEGF-Inhibitor Drugs in the 2012 United States Medicare Population: Bevacizumab, Ranibizumab, and Aflibercept. Ophthalmic surgery, lasers & imaging retina. 2016 Jun;47(6):555–62.
Baisiwala, Shivani, et al. “Physician Utilization Patterns for VEGF-Inhibitor Drugs in the 2012 United States Medicare Population: Bevacizumab, Ranibizumab, and Aflibercept.Ophthalmic Surgery, Lasers & Imaging Retina, vol. 47, no. 6, June 2016, pp. 555–62. Epmc, doi:10.3928/23258160-20160601-07.
Baisiwala S, Bundorf MK, Pershing S. Physician Utilization Patterns for VEGF-Inhibitor Drugs in the 2012 United States Medicare Population: Bevacizumab, Ranibizumab, and Aflibercept. Ophthalmic surgery, lasers & imaging retina. 2016 Jun;47(6):555–562.

Published In

Ophthalmic surgery, lasers & imaging retina

DOI

EISSN

2325-8179

ISSN

2325-8160

Publication Date

June 2016

Volume

47

Issue

6

Start / End Page

555 / 562

Related Subject Headings

  • Vascular Endothelial Growth Factor A
  • United States
  • Tomography, Optical Coherence
  • Retrospective Studies
  • Recombinant Fusion Proteins
  • Receptors, Vascular Endothelial Growth Factor
  • Ranibizumab
  • Population Surveillance
  • Ophthalmologists
  • Medicare